S.R. 206 Summary

• Requests the Department of Health to convene a Medicinal Psychedelics Right-to-Try Task Force to develop a program granting qualifying terminally ill patients access to non-FDA-approved psychedelic drugs, including psilocybin and psilocin.

• Task force must examine federal and state laws, eligible psychedelic drug types, patient qualification conditions, distribution methods, patient costs, insurance coverage, and statutory protections for patients and healthcare providers.

• Task force membership includes the Director of Health (chair), Attorney General, University of Hawaii faculty, legislative committee chairs, clinical practitioners, and representatives from the Drug Policy Forum of Hawaii, Clarity Project, Hawaii Psychiatric Medical Association, and the psychedelics industry.

• Task force must submit a preliminary report by twenty days before the 2024 regular legislative session and a final report with proposed legislation by twenty days before the 2025 regular legislative session.

• Task force is required to dissolve on July 1, 2025.